As Apple Inc. (AAPL) prepares to launch its newest iPhone model on Tuesday, JPMorgan analysts said the "main variable" heading into the launch is the specific week the iPhone X will become available.

The OLED iPhone X will likely ship in October, analysts wrote in a Monday note, as Apple is thought to have started volume production in September. For every 1 million iPhone X units sold, there are a "few million" units of impact on JPMorgan's December earnings forecast for Apple.

Price "is a smaller but also relevant variable." The OLED 265GB model is expected to retail for $1,100, JPMorgan wrote, with regular LCD models priced similarly to iPhone 7 cost structure. But price elasticity is "low in the luxury market that this device is targeting."

Apple is also expected to unveil new Apple Watch and Apple TV products at the Tuesday event in Cupertino, Calif. "The most important thing that Apple is likely to say about the Apple TV financially relates to the content available on the device," analysts wrote. Amazon.com Inc.'s (AMZN) Amazon Prime Video is predicted to be available on this rendition of the Apple TV.

Apple stock traded up 1.8% to $161.46 midday Monday.

Apple is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer buys or sells AAPL? Learn more now.

More of What's Trending on TheStreet:

More from Stocks

Medtronic Stock Is Showing Promise on the Daily Chart

Medtronic Stock Is Showing Promise on the Daily Chart

In Case You Missed It: Expect More Volatility, Netflix Down After Analyst Praise

In Case You Missed It: Expect More Volatility, Netflix Down After Analyst Praise

It's Important That Average Investors Understand Beta and What It Measures

It's Important That Average Investors Understand Beta and What It Measures

Dow Rises on Report China Offering Import Boost to Eliminate Trade Imbalance

Dow Rises on Report China Offering Import Boost to Eliminate Trade Imbalance

Here's How I Would Handle Speculative Sangamo Therapeutics

Here's How I Would Handle Speculative Sangamo Therapeutics